Skip to main content

Daurismo Side Effects

Generic name: glasdegib

Medically reviewed by Last updated on Apr 16, 2023.

Note: This document contains side effect information about glasdegib. Some dosage forms listed on this page may not apply to the brand name Daurismo.

Applies to glasdegib: oral tablet.


Oral route (Tablet)

Warning: Embryo-Fetal ToxicityGlasdegib can cause embryo-fetal death or severe birth defects when administered to a pregnant woman. Glasdegib is embryotoxic, fetotoxic, and teratogenic in animals. Conduct pregnancy testing in females of reproductive potential prior to initiation of glasdegib treatment. Advise females of reproductive potential to use effective contraception during treatment with glasdegib and for at least 30 days after the last dose. Advise males of the potential risk of glasdegib exposure through semen and to use condoms with a pregnant partner or a female partner of reproductive potential during treatment with glasdegib and for at least 30 days after the last dose to avoid potential drug exposure.

Serious side effects of Daurismo

Along with its needed effects, glasdegib (the active ingredient contained in Daurismo) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking glasdegib:

More common

Other side effects of Daurismo

Some side effects of glasdegib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects.

Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More common

For Healthcare Professionals

Applies to glasdegib: oral tablet.


Very common (10% or more): Anemia (43%), hemorrhage (e.g., petechiae, epistaxis, hematoma, contusion, rectal hemorrhage, anal hemorrhage, ecchymosis, gingival bleeding, hematuria, mouth hemorrhage, purpura, cerebral hemorrhage, eye contusion, eye hemorrhage, gastric hemorrhage, GI hemorrhage, hematemesis, hemoptysis, implant site hematoma, injection site bruising, retroperitoneal hematoma, thrombotic thrombocytopenic purpura, tracheal hemorrhage, conjunctival hemorrhage, disseminated intravascular coagulation, eyelid hematoma, hematochezia, hemorrhage intracranial, hemorrhoidal hemorrhage, lower GI hemorrhage, retinal hemorrhage, subdural hematoma) (36%), febrile neutropenia (31%0, thrombocytopenia (30%), platelet count decreased (15%), white blood cell count decreased (11%)[Ref]


Very common (10% or more): Musculoskeletal pain (e.g., pain in extremity, arthralgia, back pain, myalgia, musculoskeletal pain, musculoskeletal chest pain, neck pain, bone pain (30%), creatine phosphokinase (CPK) increased (16%), muscle tightness/spasm (15%)[Ref]


Very common (10% or more): Hyponatremia (54%), hypomagnesemia (33%), edema (e.g., edema peripheral, edema, fluid overload, fluid retention, swelling face) (30%), decreased appetite (21%), hypokalemia (15%), weight loss (13%)[Ref]


Very common (10% or more): AST increased (28%), alkaline phosphatase increased (23%)[Ref]


Very common (10% or more): Dyspnea (e.g., dyspnea, hypoxia, bronchospasm, respiratory failure (23%), pneumonia (e.g., pneumonia, pneumonia aspiration, lung infection) (19%), cough (18%)[Ref]


Very common (10% or more): Asthenia/fatigue (36%), pyrexia (18%)[Ref]

Nervous system

Very common (10% or more): Dysgeusia/ageusia (21%), dizziness (18%), headache (12%)[Ref]


Very common (10% or more): Creatinine increased (96%), renal insufficiency (e.g., acute kidney injury, blood creatinine increased, oliguria, renal failure) (19%)[Ref]


Very common (10% or more): Atrial arrhythmia (e.g., atrial fibrillation, bradycardia, tachycardia, sinus tachycardia) (13%), chest pain (e.g., chest pain, non-cardiac chest pain) (12%)

Common (1% to 10%): QT interval prolongation[Ref]


Very common (10% or more): Rash (e.g., rash, pruritus, erythema, skin ulcer, rash maculopapular, rash pruritic (20%)

Common (1% to 10%): Alopecia[Ref]


Very common (10% or more): Nausea (29%), mucositis (e.g., mucosal inflammation, oropharyngeal pain, stomatitis, anal ulcer, gingival pain, laryngeal inflammation, esophagitis, oral pain, aphthous ulcer, mouth ulceration, pharyngeal inflammation) (21%), constipation (20%), diarrhea (18%), vomiting (18%)

Common (1% to 10%): Loose tooth, toothache[Ref]

Frequently asked questions


1. Product Information. Daurismo (glasdegib). Pfizer U.S. Pharmaceuticals Group. 2018.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.